Tekla Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Tekla Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-77,061	Closed	-$92K	–	218
2019 Q4	$92K	Hold	77,061	–	–	﹤0.01%	211
2019 Q3	$116K	Sell	77,061 -151,435	-66%	-$354K	0.01%	187
2019 Q2	$919K	Hold	228,496	–	–	0.04%	168
2019 Q1	$983K	Hold	228,496	–	–	0.04%	163
2018 Q4	$1.31M	Sell	228,496 -123,122	-35%	-$908K	0.06%	149
2018 Q3	$4.77M	Sell	351,618 -503,850	-59%	-$5.28M	0.17%	95
2018 Q2	$10.2M	Hold	855,468	–	–	0.39%	60
2018 Q1	$9.61M	Sell	855,468 -79,900	-9%	-$699K	0.37%	58
2017 Q4	$6.25M	Hold	935,368	–	–	0.24%	78
2017 Q3	$7.66M	Sell	935,368 -531,000	-36%	-$3.32M	0.27%	69
2017 Q2	$6.58M	Hold	1,466,368	–	–	0.24%	77
2017 Q1	$8.08M	Buy	1,466,368 +900,000	+159%	+$3.94M	0.31%	65
2016 Q4	$2.29M	Hold	566,368	–	–	0.1%	101
2016 Q3	$3.99M	Buy	566,368 +269,434	+91%	+$2.06M	0.15%	92
2016 Q2	$2.42M	Hold	296,934	–	–	0.1%	123
2016 Q1	$2.41M	Hold	296,934	–	–	0.1%	110
2015 Q4	$3.58M	Buy	296,934 +15,000	+5%	+$147K	0.13%	101
2015 Q3	$3.38M	Buy	281,934 +254,434	+925%	+$3.59M	0.12%	120
2015 Q2	$504K	Buy	+27,500	New	+$472K	0.02%	110

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tekla Capital Management's ADAP Position: Q1 2020 in Review

Tekla Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2020, closing a stake of 77,061 shares — an estimated $92K sold.

Tekla Capital Management first reported a position in ADAP in Q2 2015 and held it in 19 quarters. The position peaked at $10.2M in Q2 2018. 47 funds tracked by Wall St. Rank hold ADAP as of Q1 2020.

Tekla Capital Management reported no remaining Adaptimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Tekla Capital Management sold 77,061 Adaptimmune Therapeutics shares in Q1 2020, an estimated $92K.
Tekla Capital Management first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 19 quarters.
Tekla Capital Management's Adaptimmune Therapeutics position peaked at $10.2M in Q2 2018.
47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2020.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.